Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings Routine +

Aurora Spine Corporation Announces First Quarter FY26 Financial Results

Aurora Spine Stabilizes Operations with First EBITDAC Profit, Yet Revenue Stagnation and Cash Burn Raise Liquidity Concerns

By The Northwire Desk — AI Analysis May 28, 2026 · 07:15 ASG · 0.245 Aurora Spine Corporation
Executive Summary
  • Aurora Spine Corporation reported Q1 FY26 financial results ending March 31, 2026.
  • Total revenues were $4.44 million, a marginal increase of 0.4% compared to $4.42 million in Q1 2025.
  • Gross profit margin improved significantly to 62.6% from 58.0% in the prior year period.
  • EBITDAC turned positive at $106,765, a substantial improvement over the $(20,924) loss recorded in Q1 2025.
  • Net loss narrowed to $(202,854) from $(349,678) in the prior year period.
  • Biologics sales surged 124% year-over-year to $0.2 million, though this remains a small portion of total revenue.
  • Cash balance decreased to $778,006 as of March 31, 2026, down from $896,713 at December 31, 2025.
  • CEO Trent Northcutt noted a slower than anticipated start to the fiscal year and expects Q2 revenue to be flat or decline slightly while improving the sales team.
Material Impact
  • The news confirms a continuation of the operational turnaround initiated in FY25, specifically regarding profitability (EBITDAC) and margins.
  • However, top-line growth is effectively stagnant at 0.4%, which contradicts management's earlier projections for biologics to drive >30% revenue growth.
  • The cash burn rate remains a critical concern; the company burned approximately $118,707 in Q1 alone, reducing runway without new capital or significant sales acceleration.
  • The positive EBITDAC is material for solvency perception but does not offset the risk of dilution if equity financing is required soon given the cash position relative to debt obligations.
  • Guidance for Q2 being "flat or take a small step back" suggests limited near-term upside potential, capping immediate stock price appreciation despite the profit milestone.
ASG · Price
Company Overview
  • Aurora Spine Corporation develops orthopedic implants focused on spinal fusion and bone density-matched solutions.
  • Flagship technology includes the DEXA Technology platform which matches implant architecture to patient bone density measurements (U.S. Patent No. 12,605,252 B2).
  • Product portfolio consists of mechanical systems (Zip implant, Hydra ARO Lumbar Fusion System) and biologics (TURBO FUSE, OSTEO GRAFT).
  • The company is pivoting from distributor reliance to an internal sales force model to improve gross margins.
Read the original news release →

More from Aurora Spine Corporation

May 07, 2026 · 07:15

Patent Milestone Masks Cash Strain and Debt Overhang Despite EBITDAC Turnaround

Other Apr 30, 2026 · 07:15

Aurora Spine Posts Record Revenue as Turnaround Strategy Takes Hold

Earnings Mar 04, 2026 · 18:28

Aurora Spine cuts loan rate, extends insider note

Financings Mar 04, 2026 · 17:01

AURORA SPINE CORPORATION ANNOUNCES AMENDMENT TO LOAN FROM INSIDER

Financings Jan 08, 2026 · 16:28

Aurora Spine receives two U.S. patents

M&A / Property Nov 18, 2025 · 07:15

Aurora Spine Corporation Announces Record Third Quarter Financial Results

Earnings